Research
Home
Technology Platform
Biopharmaceutical
Biomarkers
Molecular Binding
Receptor and Ligand
RNA Interference
High-throughput Screening
High-content Screening
Biotechnology
Biodefense
Bioinformatics
|
 | ||
| High-content
Screening
|
||
|
High-content-screening assays offer the potential to address many of the
bottlenecks currently encountered in drug discovery. Because these assays
provide researchers with large amounts of biological and chemical information,
they offer important enhancements to information obtained through traditional
affinity-based screens. Importantly, insights from these information-rich assays
could help researchers discover the most effective drugs more efficiently, while
getting flawed compounds to "fail fast," thus saving considerable time and
expense. These assays can be used across nearly all stages of the drug discovery
and development process, including target identification and validation, lead
selection and optimization, and preclinical studies. Pharmacom is interested at technologies to improve information obtained from cellular assays and other high-content studies: -Obtaining high-quality information about drug targets and potential drug candidates -Toxicity screening -Identifying leads that might be useful for treating complex diseases -Testing for interaction of a compound with orphan receptors or other targets with unknown functions -Target Identification, Qualification, and Validation -Lead Discovery and Selection -Lead Optimization and Prioritization -Preclinical and Clinical Testing | ||
 |
|
|
Pharmacom
Copyright
1997-2007
